Precision Medicine Brochure

November 18, 2019

Recent data suggests that clinical trials using biomarkers – including genomic biomarkers – are twice as likely to succeed versus those that don’t.1 According to a 2018 analysis, The Innovation Imperative: The Future of Drug Development, by the Economist Intelligence Unit (EIU) and commissioned by Parexel, drugs developed using innovative trial methods, including precision medicine trial designs, are adopted by payers more quickly.2 In short, payers want to know which patients are more likely to avoid making reimbursements for ineffective treatments.

Previous Article
Drug development innovations that work: Precision medicine
Drug development innovations that work: Precision medicine

Learn more about new regulatory frameworks for precision medicine and how best to demonstrate results for r...

Next Flipbook
Navigating the Increasing Complexity of Drug Biomarker Co-Development
Navigating the Increasing Complexity of Drug Biomarker Co-Development

Learn about five steps that will help companies better manage the complexity and risk of working with targe...

×

Speak to a Parexel® Biotech expert today!

First Name
Last Name
Job Title
Company Name
Country
Tell us how we can help
Thank you!
Error - something went wrong!